MedTrace Logo

Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

NCT01646671 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2015-10-23

Study results available
· View outcomes & findings →

Summary

This study assessed the safety, tolerability, and efficacy of LCZ696 in severe hypertensive Japanese patients

Conditions

  • Severe Hypertension

Interventions

DRUG

LCZ696

LCZ696 200 mg tablet once daily

DRUG

LCZ696

2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily

DRUG

LCZ696

2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01646671 on ClinicalTrials.gov